- Home
- HWBK vs LYEL Comparison
HWBK vs LYEL Comparison
Compare HWBK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWBK
- LYEL
- Stock Information
- Founded
- HWBK 1865
- LYEL 2018
- Country
- HWBK United States
- LYEL United States
- Employees
- HWBK N/A
- LYEL N/A
- Industry
- HWBK Major Banks
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- HWBK Finance
- LYEL Health Care
- Exchange
- HWBK Nasdaq
- LYEL Nasdaq
- Market Cap
- HWBK 218.6M
- LYEL 207.7M
- IPO Year
- HWBK N/A
- LYEL 2021
- Fundamental
- Price
- HWBK $31.16
- LYEL $12.31
- Analyst Decision
- HWBK
- LYEL Sell
- Analyst Count
- HWBK 0
- LYEL 2
- Target Price
- HWBK N/A
- LYEL $15.00
- AVG Volume (30 Days)
- HWBK 7.2K
- LYEL 25.4K
- Earning Date
- HWBK 10-29-2025
- LYEL 11-06-2025
- Dividend Yield
- HWBK 2.55%
- LYEL N/A
- EPS Growth
- HWBK 396.63
- LYEL N/A
- EPS
- HWBK 2.96
- LYEL N/A
- Revenue
- HWBK $75,021,000.00
- LYEL $60,000.00
- Revenue This Year
- HWBK N/A
- LYEL N/A
- Revenue Next Year
- HWBK N/A
- LYEL N/A
- P/E Ratio
- HWBK $10.58
- LYEL N/A
- Revenue Growth
- HWBK 33.44
- LYEL 11.11
- 52 Week Low
- HWBK $21.35
- LYEL $7.65
- 52 Week High
- HWBK $35.95
- LYEL $32.00
- Technical
- Relative Strength Index (RSI)
- HWBK 48.91
- LYEL 54.52
- Support Level
- HWBK $30.87
- LYEL $12.59
- Resistance Level
- HWBK $33.40
- LYEL $13.62
- Average True Range (ATR)
- HWBK 0.87
- LYEL 0.72
- MACD
- HWBK -0.20
- LYEL 0.06
- Stochastic Oscillator
- HWBK 10.00
- LYEL 54.24
About HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.